Enveric Biosciences, Inc. (ENVB) intrinsic value & 10-year financials
Enveric Biosciences, Inc. (ENVB) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.38
- Market cap
- $461.9K
- Revenue (FY2025)
- —
- Revenue growth (10-yr CAGR)
- 3.4%
- ROIC (10-yr avg)
- -290.5%
- Free cash flow (FY2025)
- —
ENVB 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$8.8M | -$36.24 | — | — | -304.0% |
| FY2024 | — | -$9.6M | -$19.04 | — | — | -542.8% |
| FY2023 | — | -$17.3M | -$8.09 | -$14.1M | — | -197.8% |
| FY2022 | — | -$18.5M | -$13.00 | -$17.7M | — | -505.6% |
| FY2021 | — | -$49.0M | — | -$11.6M | — | -1117.5% |
| FY2020 | — | -$6.9M | — | — | — | -43.4% |
| FY2019 | $39.9M | -$5.6M | -$2.83 | — | -15.8% | -50.2% |
| FY2018 | $43.0M | -$16.9M | -$0.82 | — | -16.6% | -55.3% |
| FY2017 | $48.6M | -$9.1M | -$0.75 | — | -24.6% | -66.1% |
| FY2016 | $36.1M | -$2.8M | -$0.21 | — | -14.9% | -22.0% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Enveric Biosciences, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Enveric Biosciences, Inc. has historically struggled to out-earn its cost of capital, averaging just -26.4% ROIC.
Over the decade, Enveric Biosciences, Inc. shows that management has aggressively returned capital to shareholders by retiring 97.4% of outstanding shares.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Enveric Biosciences, Inc. is modeled at 3.4% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-475.87 per share.